Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia

Mežnar et al., NCT04355026, NCT04355026, Jul 2020

TMPRSS2 inhibitors for COVID-19

19th treatment shown to reduce risk in April 2021, now with p = 0.00063 from 29 studies.
Lower risk for mortality, ventilation, and recovery.

No treatment is 100% effective.
Protocols combine treatments.

Estimated 90 patient TMPRSS2 inhibitor + HCQ late treatment RCT with results not reported over 6 years after estimated completion.
7 TMPRSS2 inhibitors RCTs have results missing long after expected1-7
The trials report a total of 1,116 patients, with 3 trials having actual enrollment of 142, and the remainder estimated.
Study covers TMPRSS2 inhibitors, bromhexine, and HCQ.
Mežnar et al., 31 Jul 2020, Randomized Controlled Trial, this trial uses multiple treatments in the treatment arm (combined with HCQ) - results of individual treatments may vary, trial NCT04355026 (history).
Late treatment
is less effective